Acerca de

Q&As

 

How does MSM benefit the body?

The human body greatly benefits from MSM and these essential benefits begin at the cellular level. Athletes from all sports and fields use MSM to support stronger and more flexible joints, stronger tendons and ligaments, in addition to the many other benefits associated with MSM. Doctors and other health care professionals recommend patients use MSM to assist in reducing inflammation, increase blood flow, assist patients with thickening arteries, and many other symptoms, such as:

 

Gastrointestinal/Metabolism

MSM promotes proper digestion and absorption of nutrients. MSM supports healthy metabolism and digestion and assimilation of starches, fats and proteins.

 

Hair, Skin, and Nails

Sulfur is necessary for the production of collagen and keratin. These are the primary proteins that make up hair, skin, and nails. MSM supports tissue pliability and encourages the body's ability to repair damaged skin.

 

Respiratory System

MSM assists healthy lung function by supporting the cell membranes involved in oxygen and carbon dioxide exchange.

 

Allergies

MSM helps the body maintain its natural barriers against allergens, which alleviates the allergic response to pollen, dander and foods. MSM supports the integrity of healthy mucous membrane tissue.

​

 

What is unique about Suvida's MSM formulation?

SuVida’s MSM formulation features the highest quality MSM available. To ensure maximum absorption Suvida's formulation includes the perfect ratio of Citrus C, Bioflavonoids, and Folic Acid. This combination yields the greatest benefits to best support the many biochemical processes in the body. MSM occurs naturally in many foods but in small amounts, however, Suvida's MSM is all-natural and gives the needed boost in MSM your body needs to support stronger and healthier joints. To ensure cellular delivery, Suvida's MSM also includes a broad-spectrum enzyme blend, and 72 ionic trace sea minerals. When taken in combination with our powerful Maritime Pine Plus antioxidant, professionals and consumers has reported even stronger results with increased joint comfort and greater range of motion.

 

Where is MSM found, and what is Suvida's MSM derived from?

MSM is found in the ocean within microscopic plants called plankton. These plants release sulfur compounds or salts that are transformed in the ocean water into the compound dimethyl sulfide (DMS). DMS is volatile and escapes from the ocean as a gas, it then rises into the atmosphere, and in the presence of ozone and high-energy ultraviolet light, is converted into MSM. MSM is water soluble and returns to earth in the form of rain. On earth, plants take MSM into their root systems and concentrate it. MSM and the essential sulfur it contains is basic to plant structure and plant life. Ultimately, MSM makes its way back to the sea or ocean via the plant's mineralized metabolic process (the plant's metabolism). Suvida's MSM is derived from all-natural sources of DMS and is produced by twice oxidizing DMS to form DMSO2, which is also known as MSM.

​

Using MSM in Conjunction with an Antioxidant

The most effective results with MSM are reported among professionals and customers when taken in conjunction with a high quality and diverse antioxidant. Suvida Maritime Pine Plus and Ultra Pine Plus formulations are the most effective and diverse antioxidant blends available. For the most effective and notable joint relief, try taking one of these powerful antioxidant blends in combination with MSM.

​

What research has been conducted on MSM?

Below we have included just a few of the many human clinical trials conducted on MSM. Many clinical trials and studies have also been conducted on animals which provide convincing evidence that MSM is a critical component which supports healthy joints and joint function.

​

Radboud University - Netherlands.

Engelke UF, Tangerman A, Willemsen MA, et al. Dimethyl sulfone [MSM] in human cerebrospinal fluid and blood plasma confirmed by one-dimensional (1)H and two-dimensional (1)H-(13)C NMR. NMR Bio Med 2005;18:33l-6. Radboud University Nijmegen Medical Centre, Laboratory of Pediatrics and Neurology, L-6500 HB Nijmegen, The Netherlands. [Abstract on PubMed]

(1)H-NMR spectroscopy at 500 MHz was used to confirm that a previously unidentified singlet resonance at 3.14 ppm in the spectra of cerebrospinal fluid and plasma samples corresponds to dimethyl sulfone (DMSO(2)). A triple resonance inverse cryogenic NMR probe, with pre-amplifier and the RF-coils cooled to low temperature, was used to obtain an (1)H-(13)C HSQC spectrum of CSF containing 8 microM (753 ng/ml) DMSO(2). The (1)H-(13)C correlation signal for DMSO(2) was assigned by comparison with the spectrum from an authentic reference sample. In plasma and CSF from healthy controls, the concentration of DMSO(2) ranged between 0 and 25 micromol/l. The concentration of DMSO(2) in plasma from three of four patients with severe methionine adenosyltransferase I/III (MAT I/III) deficiency was about twice the maximum observed for controls. Thus, DMSO(2) occurs as a regular metabolite at low micromolar concentrations in cerebrospinal fluid and plasma. It derives from dietary sources, from intestinal bacterial metabolism and from human endogenous methanethiol metabolism. Copyright (c) 2005 John Wiley & Sons, Ltd.

 

Tempe AZ, USA

Kim LS, Axelrod LJ, Howard P, Buratovich N, Waters RF. Efficacy of methylsulfonyl-methane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthritis and Cartilage 2006;14:286-94. Southwest College Research Institute, Southwest College of Naturopathic Medicine & Health Sciences, Tempe, AZ, USA. [Abstract on PubMed]

In 2004, Kim et al conducted a randomized, double-blind, placebo-controlled clinical trial to evaluate the effects of distilled MSM on mild to moderate osteoarthritis of the knee. Participants received 3,000 mg twice daily of either placebo or MSM (OptiMSM, Bergstrom Nutrition, Vancouver, WA)) for 12 weeks. Patients were evaluated using standardized clinical efficacy scales as well as for several secondary endpoints, adverse events, and clinical laboratory markers. Compared to placebo, those taking MSM had statistically significant reductions in pain and in difficulty performing activities of daily living. Statistically significant reductions in serum homocysteine (a risk factor for cardiovascular disease) and urinary malondialdehyde (a marker of oxidative stress) were also observed. There were no significant adverse events in the study.

 

Multi-Centered Trial

Barrager E, Veltmann JR, Schauss AG, Schiller RN. A multi-centered, open label trial on the safety and efficacy of methylsulfonylmethane in the treatment of seasonal allergic rhinitis. J Altern Complement Med 2002;8:167-74.

In a open-label study of 55 patients with seasonal allergic rhinitis (SAR; hayfever), MSM at 2600mg/day significantly reduced upper and total respiratory symptoms within 7 days; lower respiratory symptoms were significantly improved from baseline by week 3. No significant changes were observed in plasma IgE or histamine levels. Few side effects were associated with the use of MSM and no patient dropped out of the study due to adverse reactions. Energy levels increased significantly by day 14. The results suggest that MSM may be an efficacious in reducing symptoms associated with SAR.

Blum JM, Blum RI. The effect of methylsulfonylmethane (MSM) in the control of snoring. Integrative Medicine 2004;3(6)24-30. Childs SJ. Dimethyl sulfone (DMSO2) in the treatment of interstitial cystitis. Urol Clin North Am 1994;21:85-8. Dr. Childs presents six case studies on the use of intravesicular MSM for interstitial cystitis in patients who were refractory to previous therapy. Lawrence RM. Methylsulfonylmethane (M.S.M.) A double-blind study of its use in degenerative arthritis. Int J Anti-Aging Med 1998;1(1):50 [abstract]. In this abstract, Lawrence presented data on a "preliminary study" in which patients suffering from degenerative arthritis were treated with either 2,250 mg per day of MSM (Adaptin, no manufacturer specified) or placebo for an unspecified length of time. Sixteen patients were reportedly enrolled in the study. Eight received MSM and six received placebo. The author does not indicate what treatment, if any, was administered to the two remaining patients. Lawrence reported "a better than 80 percent control of pain within six weeks of beginning the study." The title of the abstract indicates that a double-blind protocol was followed.